EUVIMEDEUVIMED entdecken
Crossref

Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery

Shiqi Jiang, Xinru Lv, Zhenlin Ouyang, Hongli Chi, Yuchen Zeng, Yani Wang, Jiaxuan He, Jinling Chen, Jingyi Chen, Keli An, Ming Cheng, Yurong Wen und 2 weitere

Angewandte Chemie International Edition · 20.12.2024 · 63 (52)

DOI: 10.1002/anie.202407986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 11.11.2024. Verfasst von Shiqi Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China. Hauptthemen laut MEDLINE: Proteolysis, Doxorubicin, Single-Domain Antibodies, Drug Delivery Systems. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multispecific therapeutics hold significant promise in drug delivery, protein degradation, and cell recruitment to address clinical issues of tumor heterogeneity, resistance, and immune evasion. However, their modular engineering remains challenging. We developed a targeted degradation platform, termed multivalent nanobody‐targeting chimeras (mNbTACs), by encoding diverse nanobody codons on a circular template using DNA printing technology. The homo‐ or hetero‐ mNbTACs specifically recognized membrane targets in a multivalent manner and simultaneously recruited scavenger receptors to favor clathrin‐/caveolae‐dependent endocytosis and lysosomal degradation of multiple proteins with high efficiency and selectivity. We demonstrated that a bispecific doxorubicin‐loaded mNbTAC, named Dox o‐mvNbs PPH , passively accumulated at tumor sites, specifically interacted with PD−L1 and HER2 targets, and was rapidly transported into lysosome, inducing potent immunogenic cell death and alleviating immune checkpoint evasion. The synergistic boosting of innate and adaptive immunity promoted the infiltration and proliferation of CD8 + T cells in tumor microenvironment (an 11‐fold increase) with high toxicity and low exhaustion, eventually enhancing antitumor efficacy. Our mNbTAC platform provides multispecific therapeutics with variable valences and programmed species, whereas it induces targeted protein degradation through multireceptor‐mediated endocytosis and lysosomal degradation without the need for lysosome‐targeting receptors, representing a general and modular tool to harness extracellular proteome for disease treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisDoxorubicinSingle-Domain AntibodiesDrug Delivery SystemsHumansAnimalsMiceB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesLysosomesCell Line, TumorEndocytosis

Stichwörter der Autor:innen

cancer immunotherapydrug deliverymembrane proteinpersonalized medicineprotein degradation

Substanzen

DoxorubicinSingle-Domain AntibodiesB7-H1 AntigenErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
  • Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
  • College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310022, China.
  • Center for Microbiome Research of Med-X Institute, Department of Critical Care Medicine, Shanxi Provincial Key Laboratory of Sepsis in Critical Care Medicine, The First Affiliated Hospital, Xi'an Jiaotong University, Xi…
  • School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310022, China.

ORCID-Profile: Penghui Zhang

Förderung

  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Leading Innovation and Entrepreneurship Team
  • Pioneer R&D Program of Zhejiang

Zitieren

APA

Jiang, S., Lv, X., Ouyang, Z., Chi, H., Zeng, Y., Wang, Y., He, J., Chen, J., Chen, J., An, K., Cheng, M., Wen, Y., Li, J., & Zhang, P. (2024). Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery. Angewandte Chemie International Edition, 63(52). https://doi.org/10.1002/anie.202407986

Vancouver

Jiang S, Lv X, Ouyang Z, Chi H, Zeng Y, Wang Y, et al. Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery. Angewandte Chemie International Edition. 2024;63(52). doi:10.1002/anie.202407986

BibTeX
@article{Jiang2024,
  author = {Jiang, Shiqi and Lv, Xinru and Ouyang, Zhenlin and Chi, Hongli and Zeng, Yuchen and Wang, Yani and He, Jiaxuan and Chen, Jinling and Chen, Jingyi and An, Keli and Cheng, Ming and Wen, Yurong and Li, Juan and Zhang, Penghui},
  title = {Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  volume = {63},
  number = {52},
  doi = {10.1002/anie.202407986}
}
Kostenlos starten →